Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) soared 5.4% in pre-market trading on Tuesday, following the company's impressive fourth quarter and full-year 2024 financial results driven by the strong launch of its new eye drop XDEMVY for the treatment of Demodex blepharitis.
XDEMVY, the first FDA-approved pharmacologic treatment for Demodex blepharitis, generated net product sales of $66.4 million in Q4 2024 and $180.1 million for the full year. The product has seen broad adoption by eye care professionals across over 15,000 targets, and secured reimbursement covering more than 90% of insured lives.
While Tarsus reported a Q4 net loss of $23.1 million due to heavy investments in XDEMVY's commercial launch, management remained optimistic about the product's long-term prospects. The company is also advancing a promising pipeline, including a potential treatment for Ocular Rosacea that could drive future growth.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.